Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis

Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis

Abstract Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients are at a high risk of developing metastases in the brain. However, research focusing on treatment strategies for hormonal receptor positive (HR+), HER2+ BC patients with brain metastases (BM) remains limit...

Full description

Bibliographic Details
Main Authors: Dongshao Chen, Fei Xu, Yongkui Lu, Wen Xia, Caiwen Du, Dun Xiong, Dong Song, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Kuikui Jiang, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Shusen Wang, Ruoxi Hong
Format: Article
Language:English
Published: Nature Portfolio 2024-06-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-024-00646-2

Internet

https://doi.org/10.1038/s41523-024-00646-2

Similar Items